Evidence map›Paper›PMID 39503881›Full record

ArticleCell biology and toxicology2024

Triptolide induces hepatotoxicity by promoting ferroptosis through Nrf2 degradation.

Lin Guo, Yan Yang, Jiating Ma, Mingxuan Xiao, Rong Cao, Yang Xi, Tao Li, Tianlong Huang, Miao Yan

Abstract read
In one paragraph

Article in Cell biology and toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lin Guo *Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yan Yang *Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jiating MaDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Mingxuan XiaoSchool of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
Rong CaoSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410011, China.
Yang XiDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Tao LiDepartment of Pharmacy, Wuzhou Gongren Hospital, Wuzhou, 543000, China.
Tianlong HuangDepartment of Orthopaedic Surgery, the Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Miao YanDepartment of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China. yanmiao@csu.edu.cn.

Funding

Chinese Pharmaceutical Association CPA-Z05-ZC-2021-003National Natural Science Foundation of China 81974532Natural Science Foundation of Hunan Province 2020JJ4130Natural Science Foundation of Hunan Province 2021JJ30932Science Fund for Distinguished Young Scholars of Hunan Province 2022JJ10097Scientific Research Foundation of Hunan Provincial Education Department 21B0014
6 · The paper itself

Abstract

backgroundTriptolide (TP), a principal active substance from Tripterygium wilfordii, exhibits various pharmacological effects. However, its potential hepatotoxicity has always been a significant concern in clinical applications. PURPOSE: This research aimed to explore the involvement of ferroptosis in TP-mediated hepatic injury and the underlying mechanisms.

methodsIn this study, in vitro and in vivo experiments were involved. Hepatocyte damage caused by TP was evaluated using MTT assays, liver enzyme measurement and H&E staining technique. Ferroptosis was assessed by measuring iron level, lipid peroxide, glutathione (GSH), mitochondrial morphology and the key protein/mRNA expression implicated in ferroptosis. To verify the contribution of ferroptosis to TP-induced liver damage, the ferroptosis inhibitor Ferrostatin-1 (Fer-1) and a plasmid for overexpressing glutathione peroxidase 4 (GPX4) were employed. Subsequently, nuclear factor erythroid 2-related factor 2 (Nrf2) knockout mice and Nrf2 overexpression plasmid were utilized to investigate the underlying mechanisms. Nontargeted lipidomics was used to analyze lipid metabolism in mouse liver. Moreover, the cellular thermal shift assay (CETSA), cycloheximide (CHX) and MG132 treatments, and immunoprecipitation (IP) assays were applied to validate the binding of TP to Nrf2 and their interactions.

resultsTP triggered ferroptosis in hepatocytes, as indicated by iron accumulation and lipid peroxidation. Ferroptosis was responsible for TP-induced hepatic injury. During the process of TP-induced liver damage, the Nrf2 signaling pathway was significantly suppressed. Notably, the deletion of Nrf2 in mice aggravated the extent of liver injury and ferroptosis associated with TP, whereas enhancing Nrf2 expression in cells significantly reduced TP-induced ferroptosis. Additionally, dysregulation of lipid metabolism was associated with TP-induced liver injury. TP may directly bind to Nrf2 and enhance its degradation through the ubiquitin-proteasome pathway, thereby inhibiting or reducing Nrf2 expression.

conclusionIn summary, the suppression of Nrf2 by TP facilitated the occurrence of ferroptosis, resulting in liver damage.

Indexed as

DiterpenesEpoxy CompoundsFerroptosisHepatocytesNF-E2-Related Factor 2PhenanthrenesAnimalsChemical and Drug Induced Liver InjuryHumansLipid MetabolismLiverMaleMiceMice, Inbred C57BLMice, KnockoutProteolysisDiterpenesEpoxy CompoundsNfe2l2 protein, mouseNF-E2-Related Factor 2PhenanthrenestriptolideFerroptosisLiver injuryNrf2Triptolide

Identifiers

PMID39503881
PMCPMC11541276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.